Michael Covington Email & Phone Number

Richmond, Va, Us

Richmond, Va, Us

Expand the growth of Perseris, a long acting injectable for the treatment of adult patients suffering from the effects of schizophrenia, through engagement within hospital systems and psychiatric institutions • Ensured an appropriate and fluid transition of care into the community treatment centers• Initiated processes for the TOC team within each account and provided education to receiving treatment centers• Provided support to the Clinical Specialist team in product growth within the outpatient centers• Maintained communication with the Medical Directors for each facility and provided educational meetings regarding product information, acquisition and appropriate injection process• Ranked 1st in the nation for sales as of Q2 2024

St. Gallen, Switzerland, Ch

Asked to return to the company and develop a newly formed territory with the objectives to grow Veltassa volume, launch Korsuva and introduce a new heart failure indication for Injectafer (IV Iron) throughout Nephrology clinics and infusion centers.• Expanded breadth of prescribers through consistent virtual and live engagements, multiple programs and patient advocacy events • Leveraged existing relationships to develop advocates within newly acquired accounts• Initiated a strong pull-through campaign with physicians and staff which led to a low product abandonment rate• Launched Korsuva, a Kapa Opioid Receptor agonist for CKDaP, in dialysis patients • Created a patient centric action plan working closely with Medical Directors, Charge Nurses and Facility Administrators to have Korsuva added to protocol• Provided education for staff members on appropriate patient identification, procurement procedures and product utilization• Grew Veltassa market share by 17.5% in rolling 12 months• Increased Sales of Korsuva by 233% over rolling baseline and second highest in national new dialysis unit adoption

Tel-Aviv, Il

Joined a newly formed hospital division for a product launch. The product candidate was not approved, I was asked to return to Vifor which was now CSL Vifor.

St. Gallen, Switzerland, Ch

Promoted Veltassa for the treatment of hyperkalemia in CKD patients. Promoted Invokanna to improve glycemic control, reduce MACE and the risk of end stage renal disease in diabetic neuropathy patients.• Hired into a territory ranked 96th, growing it to 54th in 8 months• Generated new prescription growth to be 1st in the nation for 2020

Tarrytown, New York, Us

Product launch of Praluent, a first in class fully humanized recombinant monoclonal antibody injectable biologic PCSK9 Inhibitor for patients with elevated LDL cholesterol and associated acute coronary syndrome or diagnosed with rare heterozygous or homozygous familial hypercholesterolemia. • Established a more aggressive approach in treating patients with inadequately controlled LDL cholesterol within cardiology clinics, institutional accounts, DOD and Veterans Administration• Initiated treatment teams’ use of direct to HUB and specialty pharmacy services• Acquired product adoption within UVA Medical Center, VCU, Carillion Health, Augusta Health and HCA accounts• Established exclusivity within UVA’s specialty pharmacyFederal Government Account Specialist (2016 – 2017)Promoted to Federal Government Account Manager to assist in the development of new protocols and acquire product utilization within the DOD and Veterans Administration accounts for the Mid-Atlantic area (five state region)• Acquired full product adoption within the National Capital Region including Walter Reed, National Naval, Fort Belvoir and AAF Malcolm Grow Medical Center• Grew the Hunter Holmes Veterans Administration to become the 2nd highest in sales volume within the nationMedical Specialist (2017 – 2020)Managed product growth within cardiology accounts and hospitals through an organizational restructure• Took over a territory ranked 149th of 160 growing it to 114% of goal • Increased 2019 new and total prescription volume greater than district and region

Hired into Zymogenetics for the launch of Recothrom, recombinant thrombin for surgical hemostasis. Following an acquisition by Bristol Myers Squibb, The Medicines Company acquired this division where we then launched three additional products within the areas of surgical, cardiology, post operative pain management and acute bacterial infection. Additionally, we promoted an IV infusion anticoagulant. • Circle of Excellence winner 2010, 2011, 2012• Achieved full conversion within the Virginia HCA Hospital System to Recothrom which led to a national HPG contract and subsequent national HCA conversion

Malvern, Pa, Us

Product launch of Depodur, a liposomal encapsulated morphine epidural injection for postoperative pain management in major surgical procedures. Product launch of Opana ER, oxymorphone hydrochloride, to prevent physical or chemical abuse from traditional oral options for post-surgical pain control. • Nationally ranked 2nd – 2007• Product Advisory Board and Field Trainer- 2005 to 2007 • Assisted the anesthesiology team within the HCA hospitals in the development of a patient diagnostic resource to help identify opioid sensitive patients to minimize respiratory depression

New Brunswick, Nj, Us

Promoted neurological and psychiatric product line. • Nationally ranked 19th (Top 10%)• Received Regional Representative of the Year 2004

Basel, Baselstadt, Ch

Promoted neurological and psychiatric product line. • Nationally ranked 19th (Top 10%)• Received Regional Representative of the Year 2004